- Global Pharma News & Resources

Epigenetics Market Outlook, Key Financials, Segmental Revenue and Geographical Revenue till 2026

Global Epigenetics Market – Insights

Epigenetics is the study of heritable phenotype changes that do not involve alterations in the DNA sequence. Chromatin remodeling, DNA methylation, histone modification, genomic imprinting, X chromosome inactivation, and non-coding RNA regulation that affects gene transcription are some of the epigenetic alterations. Epigenetics has a significant impact on developmental biology, oncology, and drug development, non-oncological disorders such as Alzheimer ’s disease and respiratory disease, and forensic science. It finds application in identification of tissue origin, distinguishing between identical twins, paternity testing, and estimating postmortem interval.

Request for the trending sample of this report:

Increasing application and R&D in epigenetics to augment growth of the global epigenetics market

Increasing R&D in epigenetics of the genome (study called epigenomics) is expected to fuel growth of the global epigenetics market over the forecast period. Genome-wide epigenetics can significantly impact disease diagnosis. Moreover, increasing adoption of epigenetics for cancer research is also expected to boost growth of the market. For instance, in April 2018, Constellation Pharmaceuticals invested US$ 100 million for R&D of cancer epigenetics platform and ongoing ProSTAR and ORIOn-E trials, which are engineered to assess the efficacy of CPI-1205 and CPI-0610 used for cancer therapy.

Increasing government support for R&D in epigenetics is expected to boost growth of the global epigenetics market. For instance, in 2017, National Institutes of Health (NIH) planned to award 10 grants for supporting social epigenomics research in health disparities. The National Institute on Minority Health and Health Disparities (NIMHD), a part of the National Institutes of Health, committed US$ 26.2 million for nine awards over the term of five year. Moreover, in 2011, epigenetic related research was awarded US$ 11 million grant by the U.S. National Institute of Environmental Health Sciences. In same year, European Commission launched US$ 52.1 million project named BLUEPRINT, which aims to generate 100 reference epigenomes of healthy and leukaemic cells. Moreover, increasing number of projects related to whole genome sequencing including Human Genome Project has led to high adoption of epigenetic-based products, thereby aiding in growth of the market.


Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

Furthermore, high prevalence of cancer is boosting growth of the global epigenetics market over the forecast period. For instance, the Cancer Research UK, predicted the global cancer prevalence to be 32.5 million in 2012, which is expected to increase by 68% by 2030. Furthermore, according to National Cancer Institute (NCI), the number of undiagnosed cancer patients reached nearly 14.5 million in 2014, and the number is expected to reach 19 million by 2024. High incidence of chronic diseases is also expected to fuel the market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), 2012, about half of the adult in U.S, accounting to 117 million, suffers from one or more chronic health conditions such as heart disease, stroke, cancer, type 2 diabetes, obesity, and arthritis

High cost associated with epigenetics to hinder growth of the global epigenetics market

High M&R and purchasing cost of instruments such as next generation sequencing or qPCR that is used in epigenetics is expected to be hamper growth of the global epigenetics market.

North America to hold dominant position in the global epigenetics market

The market in North America is expected to account for the largest market share over the forecast period. This is expected to increasing government investment in R&D in epigenetics. Asia Pacific is expected to witness the fastest growth in the global epigenetics market over the forecast period. This is owing to increasing prevalence of cancer in the region. For instance, according to an article in Japanese Journal of Clinical Oncology in 2012, more than 70% of total cancer mortality is reported in Asia Pacific and it is projected to rise continuously to 16 million by 2025.

Global Epigenetics Market – Competitive Landscape

Key players in the market are focused on adopting collaboration and partnership strategies to expand their product portfolio. For instance, in 2012, Epizyme partnered with Summit, a subsidiary of Celgene, to develop personalized therapeutics for patients with genetically defined cancers by inhibiting histone methyl transferases (HMTs), an important epigenetic target class. Under this agreement, Celgene will receive an exclusive license outside the U.S. to some of Epizyme’s programs for the period of three years and has the right to extend this option period for one year with additional funding. Moreover, In January 2016, Merck collaborated with the Cancer Research Technology in U.K. to develop inhibitors of protein arginine methyltransferase 5 (PRMT5).

Kay players in the global epigenetics market include Merck Millipore Limited, Illumina Inc., Thermo Fisher Scientific Inc., Zymo Research Corporation, Diagenode s. a., Bio-Rad Laboratories, Inc., Qiagen Inc., Enzo Life Sciences, Inc., and New England Biolabs Inc.

To understand Research Methodology, please click

Global Epigenetics Market: Taxonomy

By Product Type

  • Consumables
    • Enzymes
    • Kits & Reagents
  • Instruments

By Application

  • Oncology
  • Developmental Biology
  • Drug Development
  • Metabolic diseases
  • Others

By End User

  • Academic & Research Institutes
  • Pharmaceuticals & Biopharmaceutical Companies
  • Contract Research Organizations (CROs)

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Other Exclusive Reports:




About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 15-Dec-2020